X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CIPLA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CIPLA ASTRAZENECA PHARMA/
CIPLA
 
P/E (TTM) x 104.6 44.6 234.8% View Chart
P/BV x 14.9 3.8 390.1% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   CIPLA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
CIPLA
Mar-17
ASTRAZENECA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,285622 206.6%   
Low Rs634458 138.3%   
Sales per share (Unadj.) Rs189.6181.9 104.3%  
Earnings per share (Unadj.) Rs-0.212.9 -1.6%  
Cash flow per share (Unadj.) Rs3.829.3 13.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs68.6155.7 44.1%  
Shares outstanding (eoy) m25.00804.51 3.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.13.0 170.4%   
Avg P/E ratio x-4,712.742.0 -11,230.0%  
P/CF ratio (eoy) x249.618.4 1,354.6%  
Price / Book Value ratio x14.03.5 403.0%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m23,988434,516 5.5%   
No. of employees `0001.623.0 6.8%   
Total wages/salary Rs m1,60526,338 6.1%   
Avg. sales/employee Rs Th3,040.26,349.1 47.9%   
Avg. wages/employee Rs Th1,029.21,143.0 90.0%   
Avg. net profit/employee Rs Th-3.3449.3 -0.7%   
INCOME DATA
Net Sales Rs m4,740146,302 3.2%  
Other income Rs m922,287 4.0%   
Total revenues Rs m4,832148,589 3.3%   
Gross profit Rs m-13024,758 -0.5%  
Depreciation Rs m10113,229 0.8%   
Interest Rs m01,594 0.0%   
Profit before tax Rs m-13912,222 -1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,798 0.3%   
Profit after tax Rs m-510,354 -0.0%  
Gross profit margin %-2.716.9 -16.2%  
Effective tax rate %-3.714.7 -24.9%   
Net profit margin %-0.17.1 -1.5%  
BALANCE SHEET DATA
Current assets Rs m2,72687,370 3.1%   
Current liabilities Rs m2,43533,081 7.4%   
Net working cap to sales %6.137.1 16.6%  
Current ratio x1.12.6 42.4%  
Inventory Days Days7487 84.8%  
Debtors Days Days4162 65.4%  
Net fixed assets Rs m1,035111,567 0.9%   
Share capital Rs m501,609 3.1%   
"Free" reserves Rs m942123,645 0.8%   
Net worth Rs m1,716125,254 1.4%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m4,156209,532 2.0%  
Interest coverage xNM8.7-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.10.7 163.3%   
Return on assets %-0.15.7 -2.1%  
Return on equity %-0.38.3 -3.6%  
Return on capital %08.5 0.0%  
Exports to sales %5.734.2 16.7%   
Imports to sales %6.58.3 77.5%   
Exports (fob) Rs m27050,050 0.5%   
Imports (cif) Rs m30612,203 2.5%   
Fx inflow Rs m37551,066 0.7%   
Fx outflow Rs m47017,678 2.7%   
Net fx Rs m-9633,388 -0.3%   
CASH FLOW
From Operations Rs m-823,824 -0.0%  
From Investments Rs m-146-13,127 1.1%  
From Financial Activity Rs m862-13,239 -6.5%  
Net Cashflow Rs m709-2,478 -28.6%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 15.7 23.7 66.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   12,856 161,166 8.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS